WGSWW — GeneDx Holdings Corp.

Summary of GeneDx Holdings Corp. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenues: $121 million, a 27% increase year-over-year.
• Full-Year Revenues: $428 million, driven by a 54% growth in exome and genome revenues.
• Exome and Genome Revenues: $104 million in Q4, up 32% year-over-year; organic growth rate was 42% when excluding a one-time payer recovery from the previous year.
• Volume: 27,761 exome and genome tests reported in Q4, with growth accelerating throughout 2025 (24% in Q1 to 34% in Q4).
• Adjusted Gross Margin: 71% for Q4, up from 65% in 2024.
• Adjusted Net Income: $4.4 million for Q4 and $4.8 million for the full year.

2. Strategic Updates and Business Highlights

• Market Leadership: GeneDx is positioned as the leader in rare disease diagnostics with the largest and most diverse dataset, INFINITY, which includes over 2.5 million rare genetic tests.
• FDA Breakthrough Device Designation: Received for its comprehensive genomic solution, enhancing its competitive edge.
• Sales Force Expansion: Nearly tripling the sales force from 50 to 150 to capture growth in new markets, particularly general pediatrics and NICU.
• New Market Initiatives: Introduction of a one-minute ordering process for general pediatricians and expansion into prenatal diagnostics.
• AI Integration: Leveraging AI tools to enhance diagnostic capabilities and efficiency.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $540 million and $555 million, with exome and genome volume growth projected at 33% to 35%.
• Market Contributions: Foundational markets (geneticists and pediatric specialists) expected to contribute 25%-27% to growth, while expansion markets (NICU, general pediatricians, and prenatal) are expected to contribute 7%-8%.
• Adjusted Gross Margin: Anticipated to remain around 70% for the year.

4. Bad News, Challenges, or Points of Concern

• Seasonal Variability: Q1 is typically a low point for volume due to deductible resets and weather impacts, with expectations of a sequential decline in tests.
• Competitive Pressures: New entrants in the market may necessitate increased efforts in education and sales to maintain market share.
• Reimbursement Risks: Initial denial rates for new outpatient markets could be high, impacting revenue until proven demand is established.
• Long Adoption Cycles: New markets like general pediatrics may take 18-24 months to ramp up significantly.

5. Notable Q&A Insights

• Guidance Confidence: Management expressed confidence in growth assumptions based on market penetration potential and the ongoing conversion from single/multigene panels to exome/genome testing.
• NICU Strategy: New leadership and a targeted approach to neonatologists are expected to drive improved utilization rates in the NICU market.
• EMR Strategy: Focus on new customer acquisition through EMR partnerships, particularly with Epic, to enhance ordering processes for general pediatricians.
• Long-Term Vision: Management remains optimistic about the transition from multigene panels to exome and genome testing as the standard for hereditary disease diagnosis.

Overall, GeneDx Holdings Corp. reported strong financial results and outlined ambitious growth plans for 2026, while also addressing potential challenges related to market dynamics and competition.